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ABSTRACT
Immune cells, including T cells, have been used for anti-cancer therapy with varying
degrees of success. One potential reason for immunotherapy failures in clinical trials may be
that typical specific pathogen free (SPF) mice do not accurately replicate human microbial
experience, which has important influence on shaping the adaptive immune response. Recently,
several previous studies have shown that the immune system of SPF mice more closely
resembles newborn human immunity, whereas immune systems from mice exposed to diverse
pathogens more closely reflect adult human immunity.
To study the impact of microbial experience on the immune response, we have adopted a
mouse model of microbial experience by co-housing SPF mice with mice purchased from a local
pet store, therefore exposing the SPF mice to various viral, bacterial, fungal, and parasitic
pathogens. Pathogen testing confirmed that the co-housed (CoH) mice are exposed to
pathogens and that the SPF controls kept in the same vivarium remain pathogen-free. We used
flow cytometry to show that CoH mice, but not SPF controls, also gain significantly more
antigen- experienced and differentiated KLRG1hiCD44hi CD8+ T cells in blood, lymph nodes and
spleen.
We injected B16 melanoma cells subcutaneously into SPF and CoH mice and monitored
tumor development and T cell activation ex vivo and in vitro. CoH tumors had increased
frequencies of KLRG1hiCD44hi CD8+ T cells compared to SPF tumors, and CoH tumor- infiltrating
CD8+ T lymphocytes exhibited increased activation upon in vitro stimulation. Lastly, CD8+ T
cells from tumors, but not spleens, of CoH mice had a higher percentage of divided cells,
indicating a potentially more effective T cell phenotype.
4

Ultimately these findings will contribute to our understanding of how microbial
experiences shape anti-tumor immunity and could have significant implications for future
immunotherapy research. We hope that CoH mice, which capture more of the individual
microbial variability seen in human patients, can be utilized as an additional model to improve
translation from immunology and oncology research in the lab to improving success rate of
human clinical trials.
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CHAPTER 1: INTRODUCTION
INTRODUCTION
Mice commercially available from different vendors have been a staple model organism
in biomedical research for over 100 years (Russell, 1985). They have provided valuable insight in
understanding basic physiologic and pathologic processes in humans, including understanding
the functions of the human immune system (Hood et al., 1983; Russell, 1985). Evidence from
various studies in recent years suggests that while specific pathogen free (SPF) mice generally
used in research have many advantages; they are not the most suitable model for
immunological and oncologic research (Abolins et al., 2017; Beura et al., 2016a; Reese et al.,
2016; Rosshart et al., 2017). Due to limited exposure to pathogens, the adaptive immune
system of SPF mice has little antigen experience and its immune state is reflective of a human
newborn infant (Beura et al., 2016a; Masopust et al., 2017; Seok et al., 2013).
The immune system of mammals can be categorized into a more general, rapidly
responding innate- and a more specific adaptive immune branch. Humans are continuously
exposed to various microbes and infected with pathogens throughout their lifespan, which
significantly shape the adaptive response, including T lymphocytes (Beura et al., 2016a;
Gerritsen & Pandit, 2016). There are various subsets of T cells based on function and these can
be further characterized by specific markers and CD8+ or “cytotoxic” T cells are specialized in
recognizing intracellular pathogens of infected cells as well as cancerous cells (Curtsinger et al.,
2003a; Gerritsen & Pandit, 2016; Gulzar & Copeland, 2004; Ioannides & Whiteside, 1993). CD8+
T cells effectively kill these cells by secreting Perforin and Granzyme B upon activation to
initiate apoptosis of infected cells (Curtsinger et al., 2003a, 2005).
11

Microbial experience influences development of antigen experienced and differentiated
CD8+ T cells. Differences in cytokine concentrations and concentrations of Granzyme B also
indicate potentially more effective CD8+ T cells in microbially experienced mice (Beura et al.,
2016a). Recent insight from complex mouse models, including wild and pet store mice, has
demonstrated that these models more closely reflect the adult human immune experience
(Abolins et al., 2017, 2018; Beura et al., 2016a; Reese et al., 2016). Additionally, various studies
in the last decade have suggested a previously underestimated importance of the commensal
microbiota in organisms on cancer development and therapy in both mice and humans (Iida et
al., 2013; Matson et al., 2018; Rosshart et al., 2017; Vétizou et al., 2015).
These findings imply a need for a more refined mouse model to study the complex
interactions of an experienced immune system with immune related diseases, such as cancer
and autoimmune disorders. Cohousing standard “clean” SPF mice with pet store mice (PS) has
been shown to successfully introduce microbial experience to the SPF mice generally used in
research, while preserving their genetic standardization (Beura et al., 2016a). We propose that
these cohoused mice (CoH) are thus an ideal complementary model to study immune- related
diseases and cancer.

PURPOSE
We previously established a mouse model with microbial experience by cohousing SPF
mice with PS mice and aim to further investigate the CD8+ T cell response in CoH versus SPF
mice. We examine how microbial experience effects the anti-tumor CD8+ T cell response by
injecting a cohort of SPF and CoH mice with B16 melanoma subcutaneously, and investigating
the activation, differentiation and effectiveness for tumor- infiltrating CD8+ T cells.
12

SCOPE
This study utilizes flow cytometry to analyze specific markers of antigen-experience,
differentiation, and effectiveness of CD8+ T cells in blood, lymph nodes, spleens and tumors of
mice. Additionally, we activate T cells in vitro to look at differences in activation markers and
Granzyme B (GzB) concentrations in different tissues and tumors of SPF versus CoH mice. We
use Enzyme-linked immunosorbent assays (ELISA) for supernatant of T cell cultures and serum
sample to quantify concentrations of Interferon γ (IFNγ), an important T cell cytokine.

ASSUMPTIONS
We have demonstrated previously that we can successfully cohouse SPF mice with PS
mice in our lab set-up (Groeber, 2019). CoH mice acquire some pathogens over the cohousing
period of 30+ days and develop distinct subsets of CD8+ T cells; SPF mice remain pathogen-free
and lack antigen-experienced, differentiated CD8+ T cells. B16 melanoma cells can be cultured
and injected subcutaneously at a predetermined concentration and mice will grow tumors in 514 days.

RESEARCH QUESTIONS
Hypothesis 1: CD8+ T cells are more antigen experienced, differentiated as indicated by
elevated markers of CD44 and KLRG1 and effective (more Granzyme B and IFNγ) in CoH mice
compared to SPF mice and respond more rapidly upon stimulation in vitro.
Hypothesis 2: Microbial experience in CoH mice positively influences the anti- melanoma
CD8+ T- cell response.
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Hypothesis 2A: There are more activated, antigen experienced (CD44hiCD69hi) and
effective (more GzB and IFNγ) CD8+ T cells present in tumors of CoH versus SPF mice.
Hypothesis 2B: CoH mice have smaller tumors compared to SPF mice.

SIGNIFICANCE
CoH mice could complement and refine immune and cancer research currently done
only in SPF mice. If CD8+ T-cells of microbially experienced mice target cancerous cells more
effectively, this suggests that individual anti-cancer responses in different patients might in part
be due to differences in “education” of T cells. A mouse model with more antigen- experience
better mimics the immune state of adult humans and could improve translation from bench to
bedside, especially in understanding complex immune-related diseases such as cancer.
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CHAPTER 2: REVIEW OF LITERATURE
THE IMMUNE SYSTEM OF STANDARD LAB MICE
Studies done using laboratory strains derived from the common house mouse (Mus
musculus domesticus) have provided great insight on the physiology and genetics of diseases
such as cancer and characterizing the host immune response (Russell, 1985). Because mice are
easy to breed, have a relatively short lifespan and high reproduction rate, they are beneficial for
understanding basic physiologic and genetic principles. To examine the tumor growth, Harvardresearcher Clarence Cook Little established the first inbred mouse strains, and amongst those
also created the standard lab strain C57Bl/6 in the early 20th century (Russell, 1985). In
subsequent years, the addition of various other inbred mouse strains with distinct
susceptibilities have provided great insight of cancer genetics (Russell, 1985). In addition to
genetic and oncologic studies, mice have enabled understanding of basic components of the
immune system such as classification of MHC genes (Hood et al., 1983).
While the benefit of laboratory research done in mice is undeniable, there are also
considerable differences in the immune state of lab mice compared to humans (Beura et al.,
2016b; Mestas & Hughes, 2004; Seok et al., 2013). To reduce influence of outside variables such
as infections, temperature changes and diet, genetically identical laboratory mice are generally
kept in a very clean and controlled environment. They are commonly housed in specific
pathogen-free conditions (SPF), kept on a strict temperature and light cycle, and fed with a
standardized diet. While this is a great way to decrease influence of environmental factors on
genetic research questions, it might provide an insufficient model organism to study the
adaptive immune system (Masopust et al., 2017). The human adaptive immune system is not
15

fully developed at birth, but instead is drastically shaped by exposure to microbes, chemical and
environmental agents with aging in both humans and mice.

MICE WITH MICROBIAL EXPERIENCE REPLICATE THE ADULT HUMAN IMMUNE SYSTEM
Microbial exposure over the time span of a normal laboratory mouse kept under SPFconditions stays consistently minimal, because novel pathogens are strictly prevented from
introduction into mouse cages. Recent studies have suggested that development and
differentiation of the immune system in SPF mice might thus be insufficient to model the
immune system of an adult human (Abolins et al., 2017; Beura et al., 2016b; Reese et al., 2016;
Rosshart et al., 2017).
Studies on wild relatives of lab mouse strains in the United Kingdom have demonstrated
that the immune responses in wild mice greatly differs from that seen in laboratory animals,
which was indicated by increased production of cytokines and higher antibody titers in wild
compared to SPF animals (Abolins et al., 2017, 2018). Additionally, more CD4+ T cells, as well as
highly activated macrophages, natural killer cells and dendritic cells could be observed in wild
mice. More effector or effector- memory type T cells were present in wild and pet store mice,
compared to a higher percentage of naïve T cells in SPF mice (Abolins et al., 2017, 2018).
Similarly, these findings could also be observed in commercially available pet store mice
(PS) (Beura et al., 2016a; Ericsson et al., 2017). Characterization of the microbial diversity in two
strains of laboratory SPF mice compared to both wild and PS mice suggested a significantly
increased heterogenicity of commensal microbes living in the gut of PS mice compared to both
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wild and SPF mice purchased from Jackson laboratories. Interestingly, there were also
significant differences seen between the two vendors of lab mice (Ericsson et al., 2017).
These studies suggest a previously underestimated importance of the environment and
pathogen exposure on shaping in the immune system of mice as a common model organism in
the laboratory. This has been further researched at the University of Minnesota by specifically
investigating CD8+ T cells, which are a major part of the adaptive immune response in mammals
and target specifically intracellular pathogens and cancerous cells. Laboratory, pet store and
wild mouse blood was compared with human blood specimens by RNA sequencing. Further
analysis confirmed significant differences in cytokine levels and phenotype of CD8+ T cells in lab
mice compared to adult humans (Beura et al., 2016b). Pet store mice as well as adult human
patients, but not SPF mice, had more experienced CD8+ T cells due to previous antigen
stimulation, as indicated by increased frequencies in CD44+ T cells observed (Beura et al.,
2016b). Upregulation of CD44 has been commonly used as a marker for experience of antigens
in T cells (Schumann et al., 2015). Immune signatures of laboratory mice demonstrated striking
similarities in those observed in human neonate cord blood (Beura et al., 2016b). Taken
together, these findings implicate that the immune state of laboratory mice compares closer to
human newborns, whereas the adaptive immune system of wild and pet store mice is more
reflective of the adult human state (Beura et al., 2016b).
Therefore, further studies on the immune system aimed at translating the research into
adult human patients might highly benefit from a more refined complementary mouse model
with more microbial exposure. While it seems like a simple concept, increasing exposure to
pathogens in clean laboratory mice brings its own challenges. As detailed previously, increased
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immune exposure is desirable to model a human-like immune state, but should not come at the
cost of genetic standardization, which would introduce other unwanted variables to research
questions, as would be the case when studying wild mice. Additionally, SPF conditions have
been developed to eliminate the risk of zoonotic infections, keep maintenance, cost and sample
sizes of laboratory mice as low as possible, and thus bring many benefits as well (Masopust et
al., 2017). Figure 1 demonstrates some of the advantages and disadvantages of introducing
microbial experience to create a “dirtier” mouse model. The next paragraph will examine
different ways in how this can be achieved.

Figure 1: Cohoused mice are cost- efficient yet have a comparable immune experience to
adult humans.
Cohousing SPF mice with pet store mice generates a cost-efficient mouse model that is also
more representative of the human adult immune state. CoH mice have limited genetic
variability but increased immune experience compared to standard SPF- mice (graphic
adapted from Masopust, Sivula & Jameson, 2017).
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DIFFERENT APPROACHES TO GENERATING IMMUNOLOGICALLY EXPERIENCED MICE
To fully understand the human immune system, accurate lab model organisms are
necessary to understand the immune response, especially regarding the individual response to
infections, vaccination and immunotherapy due to commensal microbes and microbial exposure
(Beura et al., 2016b; Gopalakrishnan et al., 2018; Iida et al., 2013; Leung et al., 2018; Reese et
al., 2016; Rosshart et al., 2017; Shen et al., 2014). Purposely increasing microbial exposure of
SPF mice might help bridge the gap in translating research in immunology, microbiology and
oncology in mice to adult humans. Several different approaches on achieving microbial
experience while minimizing introduction of too many external variables are reviewed here.
Rewilding SPF mice in a seminatural environment can alter susceptibility to a parasitic
infection as well as greatly influencing the immune response compared to SPF mice kept in a lab
setup, as demonstrated by Leung et al., 2018. Exposing a common strain of C57Bl/6 lab mice to
the external environment by housing them in an outdoor cage successfully preserves genetic
standardization, but also creates a simple model with increased pathogen exposure and
enhanced gut microbial diversity (Leung et al., 2018). This concept has the major disadvantage
of being relatively expensive due to the necessities of large outdoor cages.
A more simplistic concept by Reese et al., 2016, focused on sequentially infecting
laboratory mice with four known pathogens mimicking chronic infections commonly observed in
humans. Mice were infected with two Herpesviridae, the Influenza strain WSN and the intestinal
helminth Heligomosmoides polygyrus and later vaccinated against Yellow- Fever Virus. Immune
signatures of infected and control mice were subsequently compared to human blood samples,
demonstrating that infection with only four pathogens greatly alters the immune state of lab
19

mice and generates gene signatures comparable to adult human blood samples in contrast to
cord blood (Reese et al., 2016). This could help understand individuality in anti-vaccine
responses observed in different human populations, but also raises the question whether
artificial introduction of certain pathogen species fully captures the microbial diversity that
human individuals are exposed to over their lifespan.

Figure 2: Diverse microbiota improve the host immune response against infection
Wild mouse gut microbiota transplanted into GF- lab mice (WildR) significantly improved the
immune response against a normally lethal infection. WildR mice had better survival (left)
and measures of lung damage due to influenza infection (right) compared to two control
groups of GF mice with an SPF microbiota (LabR) and normal GF mice (Lab) (Rosshart et al.,
2017).

To investigate the effects of gut microbiota diversity on the immune system of the host,
Rosshart et al., 2017, caught wild mice and biobanked the microbiota of the genetically most
similar feral population. Using fecal- oral gavage, these microbiota were then transferred to
pregnant germ-free (GF) lab mice kept in sterile conditions, which successfully passed the
experienced microbiota on to their pups (Rosshart et al., 2017). Their offspring (WildR mice) was
less likely to die when infected with the mouse version of influenza, as demonstrated in Figure
20

2. To investigate the effects of gut microbial diversity on cancer progression, colorectal
neoplastic development was induced in a subgroup of mice. In WildR mice, tumor burden,
volume, invasiveness and inflammatory scores were greatly reduced compared to standard GF
mice with an SPF microbiota (LabR) as well as normal GF mice (Lab) (Rosshart et al., 2017).
While this approach might aid in understanding the influence of gut microbial diversity on the
immune state of lab mice, it fails to capture external infections of pathogens. Additionally,
trapping and analyzing the wild mice to identify the best-matching microbiota for transfer
requires a lot of time and resources not available in many research facilities.
These previous studies demonstrate various methods to create microbial experienced
mouse models that can be tailored towards specific research questions involving the
microbiota-host interactions. They provide further insight on how the immune state is impacted
by microbes in adult humans, but also are not always ideal in keeping cost and resources low, as
seen in the models of Leung et al., 2018, and Rosshart et al., 2017. On the other hand,
sequentially infected mice provide a simple model, yet might fail to capture the full extent of
immune exposure. Therefore, we propose that “cohoused” mice are the ideal complementary
mouse model to establish standardized, yet microbially experienced mice, which builds on a
concept successfully established in a BSL-3 facility by Beura et al., 2016.

COHOUSED MICE ARE EFFECTIVE IN STUDYING THE ADAPTIVE IMMUNE SYSTEM
The idea of using “cohoused” mice (CoH) for immunology research was developed by
researchers at the University of Minnesota (Beura et al., 2016b). SPF mice are therefore
cohoused in the same cage together with commercially purchased pet store mice. The
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Table 1: Cohoused mice get infected by some of the pathogens from pet store mice.
Cohoused mice, which are laboratory mice cohoused with pet store mice for 30+ days
successfully acquire some pathogens, that are not normally observed in SPF mice. Blood
and fecal samples were tested via PCR and serology in all three groups before and after
cohousing and results are compiled (Beura et al., 2016).
previously “clean” SPF mice are a genetically standardized lab strain and become infected with
some of the pathogens common in “dirty” pet store (PS) mice (Beura et al., 2016b). To decrease
the risk of contamination of other research animals, the CoH mice in their study were kept in a
BSL-3 (Biosafety level-3) facility with normal SPF mice serving as a control group (Beura et al.,
2016b).
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Table 1 demonstrates that after a cohousing period, CoH mice were infected by about
half of the pathogens found in the PS mice. The control group of SPF mice had no microbial
exposure of the pathogens tested for by serological analysis and fecal PCR. A period of at least
30 days of cohousing has been shown to be sufficient to induce immune changes. As indicated
in Figure 3 a), markers of immune experience increase only slightly beyond 4 weeks and start to
decrease after about 60 days again (Beura et al., 2016b).

a

b

Figure 3: Cohousing SPF mice with pet store mice greatly increases the number of antigenexperienced CD8+ T cells.
As seen in a), a maximum percentage of CD44hi CD8+ T cells is reached after a cohousing
period of approximately 30 days and levels of thereafter. B) Flow cytometry plots
demonstrates the shift in CD44hiCD62Llo T cells observed during cohousing (Beura et al.,
2016).
Infections change the immune system of previously “clean” lab mice significantly.
Research published so far has mainly focused on examining the CD8+ T cell response, which is a
potent weapon of the adaptive immune system in organisms to combat intracellular infections
and cancer cells (Gerritsen & Pandit, 2016; Gulzar & Copeland, 2004; Ioannides & Whiteside,
1993). CD8+ T cells are commonly known as “cytolytic” T cells in contrast to CD4+ T- helper cells.
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Three signals are necessary for complete activation and proliferation of CD8+ T cells
(Curtsinger et al., 2007). CD8+ T cells generally have a T cell receptor (TCR) composed of an
external αβ domain that is assembled randomly, and an internal signaling domain (CD3). TCRs
only recognize their specific antigen presented by antigen- presenting cells (APCs) such as
dendritic cells. The fragment of an intracellular antigen is presented on an MHC I molecule
(Mammalian Histocompatibility Complex Class I) by the APC, although cross- presentation of

Figure 4: Three signals are necessary for full activation of T cells.
Signal 1 of T cell activation is provided by the initial interaction of MHC I, antigen
fragment and T-cell receptor (TCR), as shown on the left. Co- stimulation is essential via
additional receptor interaction between APC and T cell, for example through CD80/86 and
CD38 (Signal 2). Full effector function is only established once the T cell gets additional
stimulation through cytokines such as IFNγ or IL-12 (Signal 3).
exogenous antigens has also been observed (Curtsinger et al., 2003b). The Interaction of TCR,
antigen and MHC Class I is known as the first signal. To strengthen the interaction of MHC I and
TCR, co- stimulation provided by CD8 is necessary for full activation of the CD8+ T cells, which is
24

the second signal necessary. While this can lead to proliferation of the CD8+ T cells,
development of the cytolytic effector function characteristic of CD8+ T cells is only achieved
through additional stimulation by cytokines or adjuvants such as Interleukin 12 (IL-12) and Type
1 Interferons. This is referred to as the third signal of T cell activation (Curtsinger et al., 2003b).
This 3-step activation process is displayed in Figure 4.
Characterization of antigen experienced CD8+ T cells in wild, pet store and SPF mice
revealed significant differences: SPF mice have the least and pet store mice have the most
experienced CD8+ T cells (Beura et al., 2016b). CD44 is used as a marker to indicate previous
antigen- experience, as it remains upregulated on memory- type CD8+ T cells (Baaten et al.,
2010). Cohousing SPF mice effectively increased the antigen experience of CD8+ T cells towards
a much higher percentage of CD44+ T cells (Figure 3 b). Additionally, other markers of T cell
differentiation and experience such as KLRG1, CXCR3 and Granzyme B differed visibly between
CoH and SPF mice and CoH mice had significantly more CD8+ T cells in non-lymphoid tissues, as
seen in Figure 5 (Beura et al., 2016b).
CoH, pet store and SPF mice were also infected with the commonly used intracellular
bacterial pathogen Listeria monocytogenes to assess differences in immune function (Beura et
al., 2016b). Bacterial load in the spleens of PS and CoH mice was significantly lower than in lab
mice and comparable to the bacterial load observed in vaccinated mice. These results suggest
that changes in T cell subsets of CoH mice also provide greater resistance against infection
(Beura et al., 2016b). Thus, it seems desirable to investigate the effects of microbial exposure on
the adaptive immune system in mice by further characterizing functionality and differentiation
of CD8+ T cells in addition to established differences in antigen experience.
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DIFFERENT CD8+ T CELL SUBSETS CAN BE STUDIED IN COHOUSED MICE
So far, research has focused on characterizing the adaptive immune system in CoH mice,
targeting mainly CD8+ T cells. CD8+ T cells are a crucial part of the adaptive immune system in
mammals and primarily target intracellular pathogens such as viruses (Gerritsen & Pandit,
2016). Additionally, tumor-infiltrating lymphocytes effectively aim to kill transformed, and thus
potentially cancerous, cells (Reiser & Banerjee, 2016). Naïve T cells circulate in the blood and
lymphoid tissues of organisms and will differentiate and proliferate into potent CD8+ effector
cells upon antigen stimulation, as previously detailed. After successful clearance of the infected
or cancerous cells, the population of effector CD8+ T cells contracts and only a small group of
memory-type CD8+ T cells remains (Gerritsen & Pandit, 2016). In cases of further tumor growth,
this mechanism of T cell differentiation is disrupted through inhibitory signals from the tumor
microenvironment and/ or host immune system (Reiser & Banerjee, 2016).
Different subsets of antigen-experienced CD8+ T cells with several specific properties
have been identified to date (Chen et al., 2018). During the primary response to antigen,
effector CD8+ effector-type T cells can be further differentiated into short-lived effector cells
(SLECs) or memory precursor cells (MPECs). SLECs are KLRG1+CD127-; the majority of SLECs die
during contraction. In contrast, MPECs are generally CD127+KLRG1-, and these cells are much
more likely to form long-lived populations (Henson & Akbar, 2009). Long-lived antigen
experienced CD8+ T cells also exist such as long- lived effector cells (LLECs).
Effector cells generally die after clearance of a primary infection, but a small population
of memory- type CD8+ T cells remains to protect against subsequent infections such, central
memory, effector memory and resident memory cells (Joshi et al., 2007). It has already been
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shown that long-lived KLRG1+ CD8+ effector cells (LLECs) are very effective in fighting viral
infection (J. A. Olson et al., 2013). LLECs are characterized by a continued upregulation of the
KLRG1-receptor long after infection. This population of T cells has already been shown to have a
significant protective function against reinfection with pathogens and might thus also be
beneficial in fighting tumor cells (Renkema et al., 2019). These LLECs can be found in CoH mice
as well (Beura et al., 2016b). LLECs are an important part of the memory function of the
immune system and are not frequent in normal SPF mice, suggesting that studying the CD8+ T
cell response only in clean SPF mice misses important pieces of the adaptive immune response.
Further characterization of CD8+ T cells is necessary to fully understand differences in
functionality introduced by cohousing. We aim to compare subsets of CD44hiKLRG1hi T cells in
both SPF and CoH mice. Since we cannot usually establish a distinct positive or negative
population, we term our T cell subsets as “hi” (instead of positive) and “lo” (instead of negative).
Additionally, we will measure CD69, a marker that is upregulated on T cells and NK- cells in early
activation (Cibrián & Sánchez‐Madrid, 2017). It is used to differentiate between CD8+ T cells
that are activated rapidly in response to an acute infection and those that differentiate due to
previous antigen experience. (Simms & Ellis, 1996; Wang et al., 2011). CD69 will be
downregulated once an infection has been cleared and similar levels of CD69 hi CD8+ T cells exist
in both SPF and CoH mice (Masopust et al., 2017).
The functional properties of CD8+ T cells are characterized through intracellular staining
for Granzyme B, which is an important effector molecule in CD8+ T cells. After complete
activation, CD8+ T cells develop cytolytic functions through release of Granzyme B and Perforin
upon stimulation with their target antigen. Perforin penetrates the cell membrane of infected
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cells and allows Granzyme B to initiate apoptosis via activating caspases. CD8+ T cells will only
remain Granzyme B+ for a few weeks without further antigen stimulation and thus, memorytype CD8+ T cells lose their cytolytic properties (Nowacki et al., 2007). Figure 5 summarizes the
activation state of the CD8+ T cells and the respective presence of specific markers, such as
CD69, CD44, KLRG1 and Granzyme B.

Figure 5: The activation state of CD8+ T cells can be characterized via different markers
When a CD8+ T cell is successfully activated by the APC (antigen-presenting cell) through
the previously introduced 3 necessary signals, it rapidly upregulates CD69. This receptor is used
as a marker for early activated T cells. These cells either develop into a small pool of memorytype CD8+ T cells that can effectively respond to a subsequent infection of the same pathogen,
or into an effector-type CD8+ T cell termed SLEC (short-lived effector cell). SLECs are
characterized by downregulating CD69, but instead express CD44 as a marker for antigenexperience as well as KLRG1 as an indicator of further differentiation. SLECs effectively initiate
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apoptosis of the virus-infected or mutagenic cell by releasing Perforin and Granzyme B, the
latter of which can be used to estimate its effector function. After successfully eliminating the
target cells, most SLECs themselves die, but some also develop into so-called LLECs (long-lived
effector cells), that are crucial for long-lasting protection, also against cancer (J. A. Olson et al.,
2013; Reiser & Banerjee, 2016).
To assess whether T cells in CoH mice react more rapidly upon antigen stimulation,
spleen cells are cultured in vitro and examined using the same markers. Thus, we hope to
compare T cell characteristics across blood, spleen, lymph node and culture samples as well as
investigating subsets present in mice injected with B16 melanoma cells.

IFNY STIMULATES THE CD8+ T CELL RESPONSE
Interferon γ is an important proinflammatory cytokine stimulating a variety of immune
cells. In contrast to Type 1 Interferons, IFNγ is classified as a structurally different Type 2
Interferon and binds to its own specific receptor (Schroder et al., 2004). It is secreted by
activated macrophages, natural killer cells, Th1 CD4+ T cells and activated CD8+ T cells (Bhat et
al., 2017). CD8+ T cells receive IFNγ amongst other cytokines as a third signal of activation,
which ensures full effector function of these T cells (Curtsinger et al., 2003b). It is then also
secreted in an autocrine fashion by activated CD8+ T cells to further increase the local immune
response (Bhat et al., 2017). It has been demonstrated to be a potent necessary mediator in the
anti-tumor response of CD8+ T cells as well as their migration to antigen-presenting cells (Bhat
et al., 2017).
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There are differences in quantities of IFNγ secreted by T cells of different inbred mouse
strains. It has been demonstrated that T cells of C57/BL6 mice release higher amounts of this
cytokine than Balb/c mice, indicating better effector function of their T cells (Schroder et al.,
2004). Studies have found elevated signaling through Type I Interferon- related pathways in
both microbially experienced pet store mice as well as human adults versus unexperienced
neonates but have focused on Type I Interferons so far. IFNγ signaling has not been specifically
investigated in cohoused mice before (Beura et al., 2016b; Huggins et al., 2019). Interestingly,
Reese et al., 2016 have demonstrated higher concentrations of IFNγ as well as induction of
Interferon- related genes in their model of sequentially infected mice, but this has not been
studied in CoH mice to date (Reese et al., 2016).
Studies have also focused on characterizing the role of IFNγ in the tumor
microenvironment and specifically its contribution to anti-cancer T cell activation (Lugade et al.,
2008; Ni & Lu, 2018). IFNγ and its associated signaling pathways are crucial to stimulate the
immune response in tumors due to its effects as a proinflammatory mediator (Blankenstein &
Qin, 2003; Dobrzanski et al., 2001) . Its tumor- decreasing influence has been shown to be due
to caspase activation, induction of MHC class I and increasing chemokine expression in tumors
to promote migration and recognition of tumor cells by tumor-infiltrating T lymphocytes
(Lugade et al., 2008). Absence of IFNγ on the other hand, contributes to increased tumor
growth, possible via impaired STAT1 phosphorylation (Lugade et al., 2008). Overall, we aim to
investigate Interferon γ concentrations in CoH versus SPF mice as it seems to be one crucial
mediator in promoting improved tumor cell recognition and local migration of tumorinfiltrating CD8+ T cells.
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MICROBIOTA INFLUENCE CANCER DEVELOPMENT AND THERAPY
Many promising improvements in cancer treatment over the last decade focus on an
immunotherapeutic approach. Monoclonal antibodies against immune-regulators such as PD1,
PDL1 and CTLA4 are the most common immune drugs used in human cancer patients so far, but
adoptive immunotherapy is another important field of research based on the observation that
tumor- specific CD8+ T cells may directly kill tumor cells (Reiser & Banerjee, 2016). Adoptive
immunotherapy has been implemented successfully on some B-cell lymphomas but has been of
very limited use in solid tumors (Martinez & Moon, 2019). Some studies indicate promising
results in patients with metastatic melanoma, using autologous T cell therapy (Rosenberg et al.,
2011; Rosenberg & Dudley, 2009). Still, much remains unknown about the specific T cell
interactions within the tumor microenvironment, and how microbial experience may influence
these interactions.

Figure 6: A diverse microbiome improves cancer development and outcome in mice with
colon cancer.
Germ-free mice receiving wild mouse gut microbiota (WildR) showed reduced markers of
colon cancer. Tumor burden (D), tumor size (E), tumor invasiveness (F) and inflammation
markers (G) were significantly reduced in WildR compared to both SPF- mice (Lab) and GFmice that had received SPF-mouse microbiota by a similar procedure (LabR) (Rosshart et
al., 2017).
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Highly individual responses to immunotherapy due to variable microbiota-immune
interactions in humans have been investigated by various recent studies (Dzutsev et al., 2015;
Gopalakrishnan et al., 2018; Vétizou et al., 2015; Zitvogel et al., 2018). Several studies have
demonstrated a significant and previously underestimated influence of the gut microbiota on
cancer development and therapy both in mice and humans.
Rosshart et al., 2017, examined the effects of transfer of wild mouse gut microbiota into
laboratory strains. They have demonstrated that the diverse wild mouse microbiota of feral
mice could be successfully transferred and maintained in Germ-free laboratory mice (GF mice).
GF mice that have received the wild mouse microbiota (WildR) showed greatly improved antitumor responses compared to both normal lab mice (Lab) as well as GF-mice receiving SPF
mouse microbiota (LabR) (Rosshart et al., 2017). As seen in Figure 6, several markers to quantify

Figure 7 Microbiota impact cancer treatment in mice.
Treatment of lab mice with an artificially depleted gut microbiome through treatment with
an antibiotic (ABX) showed significantly decreased cancer survival and increased tumor
volume after chemotherapeutic treatment with Oxaliplatin (Oxp) (Iida et al., 2013).
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severity of mutagen-induced colon cancer were significantly reduced in WildR-mice compared
to both control groups with normal SPF- microbiota (Rosshart et al., 2017).
Beyond tumor development, cancer treatments such as chemotherapy might also be
influenced by commensal bacteria. This interaction was presented in a mouse study by Iida et
al., 2013, where SPF mice were treated Oxaliplatin, a potent chemotherapeutic that also
induces the immune response. As illustrated in Figure 7, artificial depletion of the mouse
microbiota by antibiotic treatment before chemotherapy significantly reduced effectiveness of
anti-cancer therapy and post-treatment survival (Iida et al., 2013). This suggests that microbial
influence is not limited to immunotherapy, but also extends to other cancer treatments.
In addition to gut bacteria, recent evidence also points towards commensal skin
microbes influencing T cell priming and development, as demonstrated in laboratory mice (Shen
et al., 2014). Further investigation on different treatments and of other cancer types is
necessary. A more accurate mouse model that captures microbial experience, such as CoH mice,
could support future studies.

COH MICE WITH B16 MELANOMA TO STUDY TUMOR- INFILTRATING CD8+ T LYMPHOCYTES
The effects of cancer have not been published a model of cohoused mice so far. As an
initial cancer model, we suggest using B16 melanoma. Cancer might be fought more effectively
by a microbially experienced mouse model compared to the standard SPF-mice. B16 melanoma
is a common, well- characterized and effective tumor model in C57BL/6 mice and has poor
immunogenicity (Turk et al., 2004). B16 melanoma in mice, just like human melanoma, is
notoriously difficult to treat as these tumors escape immune the immune system (Lechner et al.,
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2013; Overwijk & Restifo, 2001). B16 melanoma is considered a T-cell inflamed tumor, which is a
type commonly seen in human patients as well and the function and cytokine concentrations of
T cells are substantially decreased in the tumor environment (Gajewski et al., 2013).
Since recent studies have demonstrated such a significant impact of microbiota and
cancer, we aim to characterize the immune-tumor interactions in a model with microbial
experience and compare it to standard SPF- mice. It has been hypothesized that one of the
reasons for failed translation of mouse studies are because of increased immunosuppressive
cytokines and specific chemokines in humans that cannot be observed in mice (Farrar et al.,
2000; T. S. Olson & Ley, 2002). The differences in mouse vs. human immune system are not
limited to signaling molecules (Mestas & Hughes, 2004). For example, SPF mice lack certain
subsets of CD8+ T cells that can be observed in humans and recapitulated in CoH mice by
introducing microbial experience (Beura et al., 2016b; Ericsson et al., 2017; Masopust et al.,
2017).
In conclusion, mice with microbial experience might provide a better living tumor model
that can replicate the human immune state and microbial influence on shaping the immune
system more closely (Dzutsev et al., 2015; Gopalakrishnan et al., 2018; Yaddanapudi et al.,
2013). Differences in antigen- experienced and differentiated tumor-infiltrating CD8+ T cells in
mice with microbial experience could indicate a previously underestimated importance of
antigen experience in humans on the anti-cancer response. Studying the immune-cancer
interactions using cohoused mice as a simple and cost-effective model could be of major
significance in providing a better additional model in translating immunological research from
bench to bedside.
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CHAPTER 3: METHODS
MOUSE COHOUSING
Per cohort, 25- 35 young female C57/BL6 mice were ordered from Charles River, spread
equally to cages with 4-5 mice each and allowed a transition period. 2-3 cages with 5 mice each
served as the control group and were designated clean (SPF). Their handling and supplies were
strictly separated from the remaining dirty mice. 15-20 dirty mice (CoH) were cohoused with 3-5
female pet store mice for 30+ days purchased from a conventional pet store (PETCO) as feeding
mice to allow for infection with pathogens (Appendix, Figure 15). Mice were fed ad libitum and
monitored daily. Cages were changed weekly according to a strict protocol separating SPF and
CoH mice and respective supplies. Therefore, cages, lids, wires, and bottles were sprayed and
soaked in concentrated Clidox solution (1:3:1 dilution). Additionally, they were washed with
Rescue to eliminate contamination. The cohoused mice and the corresponding SPF-mice were
kept in a satellite vivarium separated from other research animals on campus. The animals were
used in accordance to the guidelines of the Institutional Animal Care and Use Committee
(IACUC) at Grand Valley State University.

PATHOGEN TESTING
Fecal and blood samples were collected on day 0 and day 30 from pet store, CoH and SPF
mice and sent to Charles River Research Animal Diagnostic Services (CR RADS) for testing against
specific pathogens. Fecal samples were pooled from designated cages of either SPF or CoH
mice.
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BLEEDS AND RNA ISOLATION
Mice were anesthetized using isoflurane and bled retro-orbitally weekly during the
cohousing span. Serum was collected from some of the blood, and the remainder of the blood
was collected into heparinized tubes for flow cytometry analysis and potential RNA isolation (for
future studies). Red blood cells were lysed with ACK lysis buffer and prepared for either RNA
isolation or flow cytometry. RNA isolation was performed according to the manufacture’s
protocol (Quiagen RNeasy mini kit). Eluted RNA was stored at -80 C for further analysis.

B16F10- OVA CELL CULTURE AND SUBCUTANEOUS B16 MELANOMA INJECTION
B16 cells were purchased and cultured in RMPI 10% complete medium (RPMI + 10% FBS
+ streptomycin/ penicillin at 5000 µg/ml and 5000 u/ml respectively + 50 µM 2Mercaptoethanol). We injected 2.5 x 105 cells per flank in 200 µl PBS subcutaneously. Each
mouse was anesthetized with isoflurane to decrease stress, facilitate handling, and ensure
proper injection in each flank. Mice were checked daily for tumors and were harvested before
day 14 or development of necrosis. Tumor growth and mouse weight were recorded daily.

HARVESTING MICE
The mouse cohorts were harvested on 3 time points after the 30-day cohousing mark to
collect blood via cardiac puncture, spleens and cervical, as well as inguinal lymph nodes
(illustrated in Figure 15, appendix). Therefore, mice were euthanized with a heavy dose of
isoflurane and cervically dislocated to ensure death. The blood was divided into heparinized
tubes for further flow cytometry analysis as well as serum collection. Spleen and lymph nodes
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were processed immediately, with an additional ACK lysis performed on spleen samples. Tumors
of mice injected with B16 melanoma were collected in separate tubes and processed similarly to
the lymph nodes. Samples were finally resuspended in FACS buffer (1x PBS with 1% FBS) and
stained with antibodies for 20+ minutes.

T-CELL IN-VITRO STIMULATION
To look at T-cell activation ex-vivo, splenocytes and tumor cells were cultured in 24-well
plates coated with an antibody cocktail (10 µg/ml anti-CD28, 5 µg/ml of anti-CD3). T cells were
cultured in RPMI- complete medium and addition of Il-2 (10 U/ml) to keep cells alive. T-cell
stimulation was examined on day 1 and day 3/ 4 of culturing by flow cytometry. Cells were
stained with markers for antigen experience (CD44), differentiation (KLRG1), effector function
(Granzyme B) and proliferation (CFSE). The level of IFNγ was measured in the supernatant of
cultures by ELISA.

FLOW CYTOMETRY AND DATA ACQUISITION
A Beckman & Coulter CytoFlex 4 channel flow cytometer was used for analysis. Samples
were prepared according to a standard protocol, resuspended in 200µl FACS buffer and were
generally run at medium speed. Blood and spleen samples as well as samples stained with
Granzyme B were fixed before analysis with a Fix/Perm FoxP3 kit, to eliminate possibly crossreacting RBCs and release intracellular Granzyme B. Samples were generally run with the same
specific antibody combinations on the harvests and bleeds, as well as for analysis of the cell
cultures. T-cells were surface- stained with antibodies purchased from Tonbo and Biolegend
against CD4, CD8, CD44, CD69 and KLRG1. Samples were fixed first and then stained with
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antibody against intracellular Granzyme B. Cell cultures were additionally stained for live/dead
cells (Tonbo) and with CFSE on day 3/4 analysis.

IFNY- ELISA
Concentrations of the cytokine Interferon γ were measured in supernatant and serum
samples via an enzyme-linked immunosorbent assay (ELISA). A complete ELISA- Kit was
purchased from Tonbo, with a standard of IFNγ provided. ELISAs were performed according to
the manufacturer’s protocol. Serum samples were diluted before analysis, spleen supernatant
samples were used undiluted for our pilot ELISA, but we suggest diluting them 1:2 prior to
analysis for future tests.

STATISTICAL ANALYSIS
Initial flow cytometry data were acquired on the preinstalled software CytExpert and
imported for detailed analysis into FlowJo LLC 10.6. Design and statistical testing were done
using Graphpad Prism 8. Significance was determined by p- Values < 0.05 using an unpaired
Student’s t- Test or multiple t-tests.
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CHAPTER 4: RESULTS
COH MICE GET INFECTED BY VARIOUS PATHOGENS OVER 30+ DAYS OF COHOUSING WITH PS MICE
Cohousing standard lab mice kept under SPF conditions with “dirtier” bunk mates
purchased from a commercial pet store is not a novel concept. CoH mice are used for research
at other universities, but not without major safety precautions employed by the University’s
administration to prevent any potential contamination or zoonotic infections. CoH mice are kept
in Biosafety- level 3 (BSL-3) facilities in most places and thus, experiments with CoH mice have
several limitations due to the strict safety regulations (Beura et al., 2016b).
Here, we report a successful and simple cohousing setup employed in a satellite vivarium
on Grand Valley State University’s campus. We cohoused SPF mice with pet store mice
purchased from a commercial vendor in the area (PETCO) and kept a control group of standard
SPF mice completely free of any pathogen contamination over a period of at least 65 days. To
test for pathogen transfer, fecal and blood samples were compiled from 2 cages of SPF and CoH
as well as 1-2 PS mice and send to Charles River Research Animal Diagnostic Services (CR-RADS)
for testing. RT-PCR on fecal samples and immunoserology performed on blood samples revealed
no novel pathogens in the SPF control group and several common bacteria, viruses and
parasites in PS mice.
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Figure 8: Gating strategy on weekly bleeds and harvests
Gating strategy employed in FlowJo to compare frequencies of CD44hiKLRG1hi and KLRG1lo
cells on weekly bleeds in both CoH and SPF mice. Lymphocytes were roughly gated off
forward- and side scatter (A), and CD8+ cells were obtained using CD8 and excluding CD4+
cells (B). Out of the CD8+ T cells, CD44hi cells were identified and separated into a
CD44hiKLRG1hi and a CD44hiKLRG1lo population, as seen in C. Gates were identical for all
blood samples per time point, and analysis was done similarly across all bleed days. Day 21
bleed of CoH 3-1 is shown here as an example.
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After a cohousing period of 30 days, about half of the pathogens from PS mice had
infected most of the CoH mice. Among the most prevalent microbes in CoH mice were Mouse
parvoviruses, Mouse adenoviruses and Theiloviruses (table 2, appendix). This caused visible
sickness in the CoH mice, usually around Day 14-23 of cohousing as indicated by apathy, runny
crusted eyes, scruffy appearance, and no appetite. Between 5-15% of CoH mice per cohort
succumbed to the infections, less than previously reported (Beura et al., 2016b).
Overall, CR-RADS testing confirmed our cohousing protocol and lab setup as well as
standard cleaning procedures as successful, as seen in 3 independent cohorts of 25-35 mice.
CoH mice were infected with several pathogens from the PS mice, while our SPF mice control
group remained completely pathogen-free.

COH MICE DEVELOP MORE ANTIGEN EXPERIENCED, DIFFERENTIATED AND EFFECTIVE CD8+ T CELLS
To examine antigen experience and differentiation of CD8+ T cells in CoH versus SPF mice, 5
mice per group were bled weekly. Blood samples were stained with specific antibodies to
quantify upregulation of certain markers on and in the CD8+ T cells of the mice. After 10-17 days
of cohousing, CoH mice, but not control SPF mice, develop a distinct population of
CD44hiKLRG1hi CD8+ T cells, as illustrated in the gating strategy employed in FlowJo (Figure 8).
SPF mice do not gain any additional antigen exposure through infection and thus do not
upregulate KLRG1 as a receptor on their CD8+ T cells to a significant degree. Therefore, in
contrast to the “dirtier” CoH mice, SPF mice do not develop this population of antigen
experienced, differentiated T cells. Initially, about 5-7% of CoH CD8+ T cells are CD44hiKLRG1hi
and this percentage steadily increases over the cohousing period (Figure 9). After about 24 days,
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the percentage of CD44hiKLRG1hi CD8+ T cells starts to level off at about 10-20% depending on
the cohort of mice and eventually decreases after about 70+ days of cohousing (Beura et al.,
2016b).

Figure 9: CoH mice develop more antigen experienced and differentiated CD8+ T cells.
Cohoused mice develop more antigen experienced, differentiated CD44hiKLRG1hi CD8+ T
cells over a cohousing period of 30 days, as seen in roughly weekly bleeds. 4-5 mice
were bled for each group and each time point. Data are shown for Cohort #2 and have
been repeated n=3 times. T-tests were used to compare groups for each time point with
p-Values consistently <0.01 (Groeber, 2019).

To examine whether the CD8+ T cells of CoH mice are not just more antigen experienced
and differentiated, but also more effective, we stained for the intracellular marker molecule
Granzyme B (GzB). GzB gets secreted only by fully activated CD8+ T cells and initiates apoptosis
in its infected target cells (Curtsinger et al., 2005). We used a similar gating strategy to obtain a
Granzyme B- positive population as seen in the first gating schematic in Figure 8 and illustrated
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in Figure 16 in the appendix section. Thus, we compared CD44hiGzBhi CD8+ T cells in CoH versus
SPF mice during 3 different bleed days. Consistent with the previous observations, CoH mice
also have significantly more CD44hiGzBhi CD8+ T cells at all bleed dates investigated. Granzyme B
was quantified in antigen experienced CD44hi CD8+ T cells.
Interestingly, as seen in Figure 10, in contrast to a steady increase in CD44hiKLRG1hi CD8+ T
cells observed in CoH mice over 30 days of pathogen exposure, the percentage of CD44 hiGzBhi
CD8+ T cells in CoH mice decreased over time. There is a rapid development of effective CD8+ T

Figure 10: CoH mice develop more antigen-experienced and potentially more effective T
cells.
Cohoused mice develop more antigen- experienced, effective CD44hiGrzBhi CD8+ T cells over a
cohousing period of 30 days, as seen in roughly weekly bleeds. Effector cells containing
Granzyme B in blood sample of CoH mice spike initially and then level off after Day 21. 4-5
mice were bled for each group and each time point. Data are shown for Cohort #3 and have
not been repeated yet.
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cells in CoH mice compared to SPF controls initially, as seen on Day 7. Almost 20% of CD8+ T
cells are positive for Granzyme B in CoH mice, which is a 10fold difference to SPF mice. The
initial spike is probably seen due to a drastic shift of mice from a former clean, SPF environment
to a cage with pathogen-infected PS mice. To combat infection of pathogens, the adaptive
immune system rapidly upregulates effector CD8+ T cells to secrete Granzyme B and target
intracellular pathogens such as viruses. After initial exposure, CD8+ T cells of CoH mice reduce
production of Granzyme B over the next 7-14 days but retain a significantly higher percentage of
about 4 times more CD44hiGzBhi CD8+ T cells until Day 28, compared to clean SPF controls. As
expected, due to the lack of pathogen exposure, no change in Granzyme B expression could be
observed in SPF mice.
Overall, CoH mice develop significantly more antigen experienced and differentiated more
CD44hiKLRG1hi CD8+ T cells compared to SPF mice over a cohousing period of 30 days.
Concurrently, more CD44hi CD8+ T cells CD8+ T cells of CoH mice also secrete significantly more
Granzyme B compared to SPF mice at all bleed days. Due to the need of effector T cells
following infection, production of Granzyme B spikes early, decreases over the first 21 days and
levels off. This in contrast to a steady development of CD44hiKLRG1hi CD8+ T cells observed in
CoH mice.

MORE ANTIGEN EXPERIENCED, DIFFERENTIATED AND EFFECTIVE CD8+ T CELLS IN DIFFERENT ORGANS
OF COH MICE

After a successful cohousing period of at least 30 days, mice were harvested at different
time points to quantify subsets of CD8+ T cells in lymph nodes and spleens in addition to blood

44

samples. Similarly, as with the bleed days, antigen experienced and differentiated more
CD44hiKLRG1hi CD8+ T cells were quantified in Lymph nodes (LN), Spleen and blood of SPF and
CoH mice on 3 different harvest days. Effector function of CD8+ T cells was quantified in spleen
by examining the percentages of CD44hiGzBhi CD8+ T cells there.
As shown in Figure 11 A-C, CoH mice had significantly more CD44hiKRLG1hi CD8+ T cells
across all 3 tissue samples. While percentages of more CD44hiKLRG1hi CD8+ T cells were lower in
lymph nodes and spleens of CoH mice compared to blood samples, they retained more antigen
experienced and differentiated CD8+ T cells in other sites than the blood. In contrast, less than
2% of CD8+ T cells of SPF mice were CD44hiKLRG1hi in all 3 tissues observed. This suggests that
development of antigen experienced and differentiated CD8+ T cells in CoH mice due to
microbial experienced is not only a transient change in CD8+ T cell subsets seen in the blood,
but also visible in more permanent homing sites of T cells such as lymph nodes and spleen.
In line with the previous observations, spleens of CoH mice also contained a significantly
higher percentage of effective CD44hiGzBhi CD8+ T cells (Figure 11, D). While the overall
percentages were decreased compared to blood samples, CoH mice had about 2.5 times more
effector T cells than the SPF controls, as indicated by a higher percentage of CD44 hiGzBhi CD8+ T
cells. Therefore, microbial experience such as in cohousing mice does not only cause a transient
change in certain CD8+ T cell subsets. Instead, it permanently increases both CD44hiKLRG1hi
CD8+ T cells not just in the blood, but also in lymph nodes and spleens, as well as potentially
increasing percentages of CD44hiGzBhi CD8+ T cells in spleens of CoH mice versus SPF controls.
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Figure 11: CoH mice have more antigen experienced, differentiated and effective CD8+ T cells in
different organs.
A-C CoH mice have more antigen- experienced and differentiated CD44hiKLRG1hi CD8+ T cells
across different organs (blood, lymph nodes, spleen) compared to SPF mice when harvested.
D CoH mice also have higher percentages of potentially more effective CD44hiGrzBhi CD8+ T
cells in the Spleen. Data are shown for 4-5 mice per group per tissue sample for Day 49
Harvest in Cohort 3. This has been repeated n=9 times, except for D.
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SPLEEN CD8+ T CELLS OF COH MICE ARE NOT ACTIVATED MORE RAPIDLY AFTER IN-VITRO
STIMULATION, BUT SECRETE SLIGHTLY MORE GRANZYME B

To examine the CD8+ T cell response in CoH versus SPF mice after activation, spleen CD8+ T
cells were isolated and cultured in vitro for 3 days following each harvest. Separate culture
plates for each day of culture analysis were coated using anti-CD28 and anti-CD3 antibodies and
incubated at 37 C to eliminate the potential of contamination. 1 ml of supernatant was stored
for ELISAs and the remaining supernatant and cell suspension was analyzed via flow cytometry
using similar markers as on the harvests.
T cells upregulate CD69 immediately following stimulation and it is thus an excellent marker
to quantify rapid activation of antigen experienced CD8+ T cells (Simms & Ellis, 1996). A
representative gating strategy done in FlowJo is shown in Figure 17 in the appendix.
Percentages of CD44hiCD69hi CD8+ T cells were thus compared between SPF and CoH mice T cell
cultures on Day 1 (early timepoint, about 16h after initiating of cultures) and Day 3 (late
timepoint, about 56h after initiating) of in vitro T cell stimulation. T cell cultures done in
previous cohorts established this timeline as the most promising.
We could not observe any significant difference in CD44hiCD69hi CD8+ T cells in CoH
compared to SPF mice on both days of in vitro stimulation (D35 Harvest). Individual variation in
both SPF and CoH mice was relatively high on both time points. Interestingly, Day 3 did not yield
much of a further increase in T cell activation, as average percentages of CD44 hiCD69hi CD8+ T
cells remained the same in SPF and CoH mice and even decreased in cultures of other time
points. In addition, CoH mice had slightly more effective CD8+ T cells after in vitro stimulation as
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indicated by higher percentages of GzBhi CD8+ T cells, but this was not significant. Figure 12
below illustrates the slight difference in spleen CD8+ T cells.

A

B

Figure 12 : CD8+ T cells of CoH mice secrete slightly more Granzyme B.
A T cells of CoH mice are stimulated more rapidly in vitro, as indicated by slightly higher
frequencies of CD44hiCD69hi CD8+ T cells cultured from spleens on both Day 1 and Day 3 of T
cell in- vitro stimulation, but this was not significant. B CD8+ T cells of CoH mice also secrete
slightly more Granzyme B, on average, than SPF mice, as seen by higher percentages of GzBhi
CD8+ T cells. Data are shown for 4 mice per group and per time point for Day 35 Harvest in
Cohort 3. This has been repeated n=4 times.

In summary, we could observe some slight trends in activation and effector function of
spleen CD8+ T cells in vitro. Both observations were not consistent across all cultures or
individual samples and failed to reach significance.
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TUMOR- INFILTRATING CD8+ T CELLS OF COH MICE ARE MORE ANTIGEN EXPERIENCED AND
DIFFERENTIATED

B16 melanoma cells were injected into a subcohort of 5 SPF and CoH mice to examine
the effects of microbial experience on tumor growth. Tumors were harvested after 11 days on
Day 65 and tumor- infiltrating T lymphocytes were stimulated in-vitro analogous to spleenderived T cells. Supernatant of tumor- infiltrating T cell cultures was analyzed on Day 1 and Day
3 to examine differences in T cell activation markers in cultures from SPF versus CoH mice
A significantly higher percentage of CD8+ T cells of CoH tumors was CD44hiKLRG1hi
compared to T cells of SPF tumors (Figure 13, A). While we had some individual variability in
percentages of CD44hiKLRG1hi CD8+ T cells in both groups, we observed similar results on two
independent tumor cohorts (compare to Groeber, 2019). It suggests that this subset of T cells
observed in significantly higher frequencies in CoH mice preferentially moves into tumor tissue
as well. However, we cannot rule out that we observe more antigen- experienced and
differentiated CD8+ T cells in tumor samples of CoH mice simply because CoH mice overall have
higher numbers of these cells. To investigate T cell effectiveness, we also quantified percentages
of CD44hiGzBhi CD8+ T cells in tumor tissue, but saw no significant difference in CoH versus SPF
mice tumor samples with a trend of more effective T cells in CoH mice (Figure 13, B).
We can conclude a significant difference in antigen experienced, differentiated
CD44hiKLRG1hi CD8+ T cells in CoH versus SPF tumors, but only saw a slight increase in
CD44hiGzBhi CD8+ T cells in tumor tissue when investigating effectiveness of the tumorinfiltrating lymphocytes.
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Figure 13: Tumor- infiltrating CD8+ T cells of CoH mice are more antigen experienced and
differentiated.
A Tumors of CoH mice have significantly more CD44hiKLRG1hi CD8+ T cells compared to
tumors of SPF mice. Data are shown for n=3 mice per group of Cohort #1 and has been
repeated n=1 time. B T cells of tumors in CoH mice not significantly more effective
compared to SPF controls, as indicated by only marginally higher frequencies of CD44hiGzBhi
CD8+ T cells. Data are shown for 4 mice per group for Day 65 Harvest in Cohort #3. This has
not been repeated yet.
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TUMOR- INFILTRATING CD8+ T CELLS ARE MORE ACTIVATED AND DIVIDE MORE RAPIDLY IN COH MICE
AFTER IN- VITRO STIMULATION

In line with the tissue observations on tumor-infiltrating lymphocytes, we also
investigated potential differences in antigen experience, activation, and effectiveness of tumorinfiltrating lymphocytes isolated from harvested B16 melanoma tumors and then stimulated in
vitro for 3 days, similar to spleen T cell cultures.
In contrast to spleen cultures, tumor- derived T cells of CoH mice were activated much
more rapidly compared to SPF mice (Figure 14, A). Even on Day 1 about 16 hours after culture
setup, there was almost a 2.5-fold difference in percentage of antigen experienced, activated
CD44hiCD69hi CD8+ T cells in tumor cultures of CoH mice versus controls. SPF mice cultures
gained more CD44hiCD69hi CD8+ T cells from Day 1 to Day 3 compared to CoH mice, but still had
significantly less antigen experienced, activated CD8+ T cells in tumor cultures on Day 3
compared to CoH mice. On average, 53.5% of SPF were CD44hiCD69hi CD8+ T cells on Day 3,
which was comparable to the percentage of antigen experienced, activated CD8+ T cells of CoH
mice on Day 1. In contrast, by Day 3, almost 3/4 of CD8+ T cells cultured from CoH mouse
tumors had a CD44hiCD69hi phenotype.
By staining T cells prior to in vitro activation with CFSE, a dye that gets 50% more diluted
per cell division, we also examined percentages of divided CD8+ T cells in tumor cultures and
compared these to divided CD8+ T cells of spleen cultures on Day 3. SPF mice had a higher
percentage of divided spleen-derived, stimulated T cells on Day 3 compared to CoH mice (Figure
14, B), but not significantly more so. Interestingly, there were significantly more divided CD8+ T
cells present in the supernatant of tumor cultures on CoH mice versus SPF mice (Figure 14, C).
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CoH mice had over 25% more divided CD8+ T cells compared to SPF controls, pointing to an
increased proliferation of CoH CD8+ T cells isolated from tumors compared to SPF controls. This
was a striking difference especially because the frequency of divided spleen T cells was higher in
SPF compared to microbially experienced CoH mice.
In summary, this suggests that microbial experience influences the anti-melanoma
response in mice. There were significantly more activated CD44hiCD69hi CD8+ T cells on both
time points of T cell in vitro stimulation in CoH versus SPF mouse tumors. Additionally, CoH mice
had a significantly higher percentage of divided CD8+ T cells present in tumor cultures on Day 3
compared to SPF mice, which was reversed when investigating frequencies of divided CD8+ T
cells cultured from spleens. This seems to suggest that the higher frequencies of antigen
experienced, differentiated, and effective CD8+ T cells observed in different organs of CoH mice
might also get activated and proliferate more effectively in presence of cancer.
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Figure 14: Tumor-infiltrating CD8+ T cells are more activated and divide more rapidly in
CoH mice.
A T cells of CoH mice are stimulated more rapidly in vitro compared to SPF controls. There
were significantly higher frequencies of CD44hiCD69hi CD8+ T cells cultured from tumors of
CoH mice on both Day 1 and Day 3 of T cell in- vitro stimulation. B Spleens of CoH mice have
slightly less divided CD8+ T cells compared to spleens of SPF mice on day 3 of T cell in vitro
stimulation. C Tumors of CoH mice have significantly more divided CD8+ T cells compared to
tumors of SPF mice on day 3 of T cell in vitro stimulation. Cells were CFSE stained for the
number of divisions and counted as “divided” beyond the first division peak CD8+ T cells.
Data are shown for 4 mice per group on Day 3 of in vitro T cell stimulation on Day 65
Harvest in Cohort 3. This has not been repeated yet. Data are shown for 4 mice per group
and per time point for Day 65 Harvest in Cohort 3. This has not been repeated yet.
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CHAPTER 5: DISCUSSION
Mice with microbial experience are slowly being explored as a beneficial complementary
mouse model for biomedical research in research facilities across the United States. Due to the
fear of contamination of other laboratory animals and the risk of contracting zoonotic
infections, safety standards usually remain stringent and make several other aspects of
immunology and oncology research with these mice difficult, such as setting up T cell cultures or
using cancer cell lines. Therefore, up to this date, no research on cancer models in microbially
experienced mice has been reported and this thesis explored a novel impact of microbial
experience on tumor development by injecting B16 melanoma cells into a subcohort of both
cohoused and SPF mice and investigate the anti-melanoma CD8+ T cell response.
Interestingly, we could already see striking differences in antigen experienced and
differentiated CD44hiKLRG1hi CD8+ T cells in a small preliminary subgroup of cohoused mice. A
trial B16 melanoma injection was done on 8 mice in our first cohort but could not be repeated
in the second cohort. We followed up on these observations with a more extensive third cohort
of 35 mice and analyzed the CD8+ populations of interest during the cohousing period, on
harvest days, after in-vitro stimulation and in tumors of CoH mice compared to SPF controls.
We could repeat observations of cohort #1 and #2 successfully and incorporated Granzyme
B as a marker that indicates the effector function of CD8+ T cells. In addition to a significant
increase in CD44hiKLRG1hi CD8+ T cells in CoH mice after 30+ days of cohousing, we observed a
significant difference in potentially more effective CD44hiGzBhi CD8+ T cells in CoH mice as well.
These CD8+ T cells spiked early during cohousing on Day 7 and then seemed to decrease to an
elevated level in CoH compared to SPF controls by day 21. In addition to differences in the
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population percentages of GzBhi CD8+ T cells, we could confirm differences in effectiveness by
evaluating the mean fluorescent intensity of Granzyme B (MFI), which was also significantly
higher in CoH mice. The MFI gives us a direct estimate of the amount of GzB produced in these T
cells rather than just investigating percentages of GzB- positive T cells.
Unfortunately, due to clogging of our flow cytometer, we lack any data on the day 14 bleed.
We aim to follow up with a more careful analysis of Granzyme B concentrations on the
subsequent cohorts to precisely determine when Granzyme B increases and decreases during
the 30- day cohousing period. Overall, differences in Granzyme B concentrations are in line with
our hypothesis that CoH mice have a more experienced and thus effective CD8+ T cell response,
indicating an overall more potent adaptive immune system. stimulated in vitro and
demonstrated higher percentages of divided CD8+ T cells.
Unexpectedly, we report no significant differences in GzBhi CD8+ T cells or MFI of Granzyme
B on both days of T cell in vitro stimulation between CoH and SPF mice. While we saw an overall
significant difference in CD44hiGzBhi CD8+ T cells in spleens of harvested CoH compared to SPF
mice, this trend was eliminated or partially reversed when spleen T cells were stimulated in
vitro. So far, we have only been able to do few repeats of our in-vitro T cell experiments, and we
hope to validate results and improve accuracy with future cohorts. Secondly, since we cannot
strictly isolate just the CD44hiGzBhi CD8+ T cells of both SPF and CoH mice to investigate in vitro
stimulation specifically on this subset, we are not sure on whether our comparisons are
accurate enough to detect any significant changes.
In addition to that, a more detailed analysis of Granzyme B frequencies on harvest and in T
cell cultures is needed, since we observed a lot of variability in between different harvest
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groups. This is probably due to spreading several pet store mice with potentially different
pathogen burdens to our cages of CoH mice. Therefore, we cannot precisely control which
pathogens infect which CoH mice. Since cages are pooled per harvest, CoH mice with variable
microbial experience are analyzed together and compared as a group to SPF controls. While this
is a condition that is difficult to eliminate, it also enhances the comparability of cohoused mice
to human patients, since human individuals can have very variable exposure to microbes over
the course of their life time, even if they are from the same location.
In future cohorts, we plan on weighing and measuring tumor size in mice to record any
potential differences in growth due to microbial exposure. We hypothesized that tumor of CoH
mice would be slightly smaller compared to SPF mice due to more activated, experienced, and
differentiated CD8+ T cells observed. Due to the lack of accurate- enough instruments, we were
not able to detect external differences in tumor development. Several studies on normal and
microbially experienced lab mice have reported differences in size and growth of tumors due to
microbial influence (Iida et al., 2013; Rosshart et al., 2017). Therefore, this is another area of
further investigation of this project.
Additionally, in future cohorts, we aim to include a more thorough analysis of Interferon y
concentrations as an additional marker to characterize differences in effectiveness of CD8+ T
cells, since Granzyme B has not been conclusive in Cohort #3. Due to time constrains and the
effects of COVID-19, we could only do one pilot ELISA on IFNγ concentrations of 6 supernatant
samples of a previous cohort. While we could see a slightly lower average concentration of IFNγ
in SPF mice supernatant samples of Day 4 T-cell culture (preliminary data shown in Figure 18,
appendix), this was not enough to detect significant differences between CoH and SPF due to a
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relatively large individual variation. Since we have only tested supernatant samples of Cohort
#1 so far via ELISA, we also cannot exclude a relatively high variability of samples due to it being
our first cohort. Concentrations of IFNγ overall also fell into the higher end of the detection
range of the ELISA test kit, as we used Day 4 as the second time point in the first T cell cultures
of Cohort #1. Therefore, these first concentrations might already be too high to detect any
meaningful differences between SPF and CoH T cells since stimulation had already been too
long. In future analyses, we would characterize earlier T cell culture time points such as Day 1
and Day 3 to investigate differences or dilute supernatant samples 1:2 prior to testing.
To obtain more CD8+ T cells in tumors, we also aim to enrich for T lymphocytes in
subsequent cohorts. On average, we only obtained percentages of about 1% of CD8+ T cells in
tumor samples, due to large amounts of other non-immune related cells such as endothelial
cells. By adding an enrichment protocol, we hope to increase the amount of tumor-infiltrating T
cells and thus also increase accuracy of the subsets investigated.
We believe that repeats of our experiments will also help support our observations. We
have seen significantly increased CD44hiKLRG1hi CD8+ T cells in two independent cohorts of 3-4
mice per group so far but have not repeated other markers on tumor- infiltrating CD8+ T cell
subsets included in this work. Subsequent tumor cohorts would be increased in size to account
for possible excluded samples such as due to systemic dissemination of tumors due to imprecise
B16 melanoma cell injections or deaths of mice after severe infections.
Lastly, while we aim to quantify T cell subsets equally in CoH and SPF mice and in T cell
cultures, we unfortunately cannot stimulate specific subsets in vitro. Essentially, we cannot
compare apples to apples, because we lack the supplies necessary to just stimulate

57

CD44hiKLRG1hi CD8+ T cells in culture or isolate exclusively these T cells from spleen tissues and
tumors for further analysis. While we only have limited markers available, we have chosen these
carefully, since they have proven to be effective in earlier studies with CoH mice (Beura et al.,
2016b). Future collaboration with more extensive labs in other research facilities such as the
University of Arizona or the University of Minnesota could also be an option to increase the
quality of our data.
In conclusion, we have successfully demonstrated that CoH, compared to SPF mice have
more antigen experienced, differentiated, and effective CD8+ T cells across different organs.
These CD8+ T cells develop during a cohousing period of 30+ days with pet store mice, which
can successfully be done in a simple satellite vivarium. This leads us to mostly accept our
Hypothesis 1 as stated in the introduction. More importantly, when injected with B16
melanoma, tumor-infiltrating CD8+ T cells in CoH mice are significantly more antigenexperienced and differentiated compared to SPF mice. They are activated more rapidly
following T cell stimulation in vitro. Additionally, CD8+ T cells from tumors of CoH mice also
show a significantly increased number of divided CD8+ T cells compared to SPF mice, suggesting
that microbial experience also influences the functional properties of tumor- infiltrating CD8+ T
cells specifically. This is in line with Hypothesis 2 a..
Various studies in the last years have demonstrated a previously underestimated impact of
commensal microbes and exposure to pathogens in shaping the immune response to various
immune related diseases and cancer. Microbial experience seems to influence the individual
immune response in both mice and human patients (Beura et al., 2016b; Frankel et al., 2017;
Iida et al., 2013; Rosato et al., 2019; Rosshart et al., 2017). With several successful
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immunotherapeutic drugs being developed to treat cancer more effectively, it is necessary to
have more accurate models to predict outcome of therapy based on the individual immune
state of human patients. Due to their limited immune experience SPF mice fail to recapitulate
many nuances of the adult human T cell response and likely the adaptive immune system as
well. Adding CoH mice as an additional model in immune-related research could improve our
understanding of the patient immune and anti-cancer response. While SPF mice have their
place in basic biomedical and immunological research due to their ease in handling, costeffectiveness and versatility, CoH mice could be implemented as an additional lab model to test
vaccines and cancer-drugs before moving into human clinical trials. This could ultimately help
reduce cost and enhance a more successful transition from bench to bedside. In summary,
cohousing lab mice could be a valuable model to increase translation of cancer- and immune
related research from lab to human patients.
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APPENDICES: TABLES AND FIGURES

Lymphocytic choriomeningitis virus
Mouse adenovirus 1 & 2
Mouse hepatitis virus
Mouse norovirus
Mousepox (Ectromelia virus)
Mouse parvovirus
MPV 1
MPV 2
MPV 3
MPV 4
Mouse rotavirus
Pneumonia virus of mice
Reovirus
Sendaivirus
Theiloviruses
Corynebacter bovis
Cilia-associated respiratory bacillus
Clostridium piliforme
Mycoplasma pulmonis
Mites
Pinworms
Aspiculuris tetraptera (pinworm)
Syphacia muris (pinworm)
Syphacia obevelata (pinworm)

total SPF
[%]

total PS
[%]

total CoH
[%]

0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0

0.0
100.0
100.0
50.0
50.0
100.0
50.0
0.0
100.0
0.0
0.0
0.0
0.0
100.0
100.0
0.0
0.0
50.0
75.0
0.0
50.0
50.0
0.0
0.0

0.0
75.0
25.0
50.0
50.0
100.0
0.0
0.0
100.0
0.0
0.0
0.0
0.0
0.0
100.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0

Table 2: CoH mice get infected by various pathogens during cohousing, while SPF mice stay
clean.
Pathogen testing by Charles River indicates that PS mice were infected with a variety of
pathogens and confirmed that CoH mice acquired about half of them during a cohousing
period of 30 days. The control group of SPF mice kept in the same satellite vivarium, in
contrast, remain completely free of any pathogens that were tested for. Data are compiled for
cohorts 1 and 2, fecal and blood samples were pooled from 2 cages for each group of mice for
each sample (Groeber, 2019).
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Figure 15: Experimental setup of our mouse cohorts
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Figure 16: Gating strategy used to compare frequencies of CD44hiGzBhi CD8+ T cells.
Gating strategy employed in FlowJo to compare frequencies of CD44 hiGzBhi and GzBlo cells on
weekly bleeds in both CoH and SPF mice. Lymphocytes were roughly gated off forward- and
side scatter (A), and CD8+ cells were obtained using CD8 and side scatter (B). Out of the CD8+
T cells, those with CD44 expression were identified and separated into a GzBhi and GzBlo
population, as seen in C. Geometric means were calculated on both CD44 hiGzBhi and -GzBlo
cells as well to compare numbers of Granzyme B in between groups. Gates were identical for
all blood samples per time point, and analysis was done similarly across all bleed days. CoH 3-1
is shown here as an example.
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Figure 17: Gating strategy examine percentages of activated CD44hiCD69hi T cells.
Gating strategy employed in FlowJo to examine activated, antigen experienced CD8+ T
cells after harvests and in-vitro stimulation. As seen in the bleed gating strategies,
lymphocytes were roughly gated off forward- and side scatter (A) and CD8+ T cells were
further gated off these lymphocytes (C). In D, CD8+ T cells were further separated into a
CD44hi (or CD44+) population and subsequently further divided into activated CD69 hi and
inactive CD69lo T cells. This was done identically for all samples per organ and time point,
and gates were employed in a similar manner across different culture and harvest days.
D65 Tu D3 Culture sample CoH 3-12 is shown here as a representative example.
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Figure 18: CoH mice have slightly higher concentrations of IFNγ.
The IFNγ concentration of supernatant samples collected after T cell in vitro stimulation from
Cohort #1 were analyzed via ELISA. On average, CoH samples had slightly higher
concentrations of IFNγ compared to SPF mice in this pilot test, but the difference observed
failed to reach statistical significance. Supernatant samples of D60 Harvest of Cohort #1 from
Day 4 of stimulation were analyzed in this ELISA, with n= 3 SPF and 3 CoH mice. This has not
been repeated yet.
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